MannKind Soars after FDA Accepts Resubmission of Inhaled Insulin

MannKind Soars after FDA Accepts Resubmission of Inhaled InsulinMannKind (MNKD) shares jumped about 10% in afternoon trading after the pharmaceutical company announced the Food and Drug Administration accepted its resubmission of its inhaled insulin, Afrezza. The FDA set a review date for Dec. 29.

Afrezza is an ultra-rapid acting mealtime insulin therapy to control hyperglycemia for adult patients with type 1 and type 2 diabetes. The drug-device combination product consists of Afrezza Inhalation Powder pre-metered into single-use dose cartridges and the Afrezza Inhaler.

In March, after a few months of delay, MannKind received a complete response letter from the FDA requesting additional information on Afrezza. MannKind, in response, submitted clinical data from a recently completed study in patients with type 1 diabetes, as well as updated pooled safety data related to the drug. It also submitted information on the comparability of MannKind's next-generation delivery system to the device that was used in pivotal clinical studies.

"We have worked diligently since March to prepare our resubmission and we are confident that we have addressed the requests that were outlined by the FDA," said Alfred Mann, chairman and CEO.
Read Full Story

Markets

DJIA 21,859.34 -40.55 -0.19%
NASDAQ 6,287.76 -9.72 -0.15%
S&P 500 2,448.45 -4.06 -0.17%
NIKKEI 225 19,434.64 50.80 0.26%
HANG SENG 27,401.67 246.99 0.91%
DAX 12,174.30 -55.04 -0.45%
USD (per EUR) 1.18 0.00 0.33%
USD (per CHF) 0.97 0.00 -0.19%
JPY (per USD) 109.10 -0.62 -0.57%
GBP (per USD) 1.28 0.00 -0.33%

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.